Muc1 in cancerous cells is distinct from normal Muc1, whereby incomplete glycosylation results in truncated side chains such as in the venerable Thomsen‐Friedrich, Tn and sialyl‐Tn antigens.[127] As a consequence, Muc1 analogues are promising cancer vaccine candidates and their syntheses have been intensively pursued. Here, MUC1 is linked to cancer.